The complex pattern of cytokines in sepsis: Association between prostaglandins, cachectin, and interleukins

Annals of Surgery

Volumn 214, Issue 2, 1991, Pages 141-148

  Ertel, Wolfgang ^a,b   Morrison, Mary H ^a   Wang, Ping ^a   Ba, Zheng F ^a   Ayala, Alfred ^a   Chaudry, Irshad H ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS;

ANIMAL; BACTERIAL INFECTIONS; CYTOKINES; DINOPROSTONE; ENDOTOXINS; IBUPROFEN; IN VITRO; INTERLEUKIN-1; INTERLEUKIN-6; MACROPHAGES; MALE; RATS; RATS, INBRED STRAINS; SPLEEN; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0025951812     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199108000-00008     Document Type: Article

References (46)

1. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166:147-153.
2. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989; 53:488-498.
3. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357.
4. De Groote MA, Martin MA, Densen P, et al. Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 1989; 262: 249-251.
5. Marks JD, Marks CB, Luce JM, et al. Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990; 141:94-97.
6. Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during sepsis in humans. Crit Care Med 1989; 17:975-978.
7. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989; 1:1122-1125.
8. Michie HR, Guillou PJ, Wilmore DW. Tumour necrosis factor and bacterial sepsis. Br J Surg 1989; 76:670-671.
9. Beutler G, Milsark IW, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (Washington, DC) 1985; 229:869-871.
10. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925-1937.
11. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF-α). Circ Shock 1990; 30:279-292.
12. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163:1433-1450.
13. Kasid A, Director EP, Rosenberg SA. Regulation of interleukin-6 (IL-6) by IL-2 and TNF-α in human peripheral blood mononuclear cells. Ann NY Acad Sci 1989; 557:564-566.
14. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2:108-115.
15. Nijsten MWN, De Groot ER, Ten Duis HJ, et al. Serum levels of interleukin-6 and acute phase response. Lancet 1987; ii:921.
16. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/ tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627-1633.
17. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256:R659-R665.
18. Ramadori G, Van Damme J, Reider H, Meyer zum Buschenfelde KH. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988; 18:1259-1264.
19. Bottoms GD, Johnson M, Ward D, et al. Release of arachidonic acid metabolites from white blood cells, platelets, smooth muscle cells and endothelial cells in response to endotoxin and A23187. Circ Shock 1986; 20:25-34.
20. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162:2163-2168.
21. Mizel SB, Dayer JM, Krane SM, Mergenhagen SE. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci USA 1981; 78:2474-2477.
22. Goodwin JS, Webb DR. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 1980; 15:106-122.
23. Kunkel SL, Chensue SW, Phan SH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol 1986; 136: 186-192.
24. Dinarello CA, Marnoy SO, Rosenwasser LJ. Role of arachidonate metabolism in the immunoregulatory function of human leukocyte pyrogen/lymphocyte activating factor/interleukin 1. J Immunol 1983; 130:890-895.
25. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 1988; 263:5380-5384.
26. Chaudry IH, Wichterman KA, Baue AE. Effect of sepsis on tissue adenine nucleotide levels. Surgery 1979; 85:205-211.
27. Kaye J, Procelli S, Tite J, et al. Both monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen in the activation of T cells. J Exp Med 1983; 158:836-856.
28. Suda T, Hodgkin P, Lee F, Zlotnik A. Biological activity of recombinant murine interleukin-6 in interleukin-1 T cell assays. J Immunol Methods 1989; 120:173-178.
29. Mizel SB. Production and quantitation of lymphocyte activating factor (interleukin 1). In Herscowitz HB, Holden HT, Bellanti JA, Ghaffar A, eds. Manual of Macrophage Methodology. New York: Marcel Dekker, 1982, pp 407-416.
30. 2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 1989; 83:9679-9683.
31. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95:99-105.
32. Eskandari MK, Nguyen DT, Kunkel SL, Remick DG. WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability. Immunol Invest 1990; 19:69-79.
33. Ayala A, Perrin MM, Meldrum DR, et al. Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine 1990; 2:170-174.
34. Ertel W, Morrison MH, Ayala A, et ai. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions following hemorrhagic shock. Ann Surg 1991; 213:265-271.
35. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-1486.
36. Marano MA, Fong Y, Moldawar LL, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170:32-38.
37. Waage A, Brandtzaeg P, Halstensen A, et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333-338.
38. Zhang Y, Lin JX, Yip YK, Vilcek J. Stimulation of interleukin-6 mRNA levels by tumor necrosis factor and interleukin-1. Ann NY Acad Sci 1989; 557:548-549.
39. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989; 142:144-147.
40. Baud L, Perez J, Friedlander G, Ardaillou R. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEB 1988; 239:50-54.
41. Atkinson TH, Murray AW, Krilis S, et al. Human tumour necrosis factor-alpha (TNF-α) directly stimulates arachidonic acid release in human neutrophils. Immunology 1990; 70:82-87.
42. 2 production of recombinant human interleukin-1 and tumour necrosis factor. Biochem Biophys Acta 1990; 1051:310-318.
43. 2 suppresses tumor necrosis factor but not interleukin-1α or β-mRNA and cell-associated bioactivity. J Leuko Biol 1989; 45:416-421.
44. Okusawa S, Gelfand JA, Ikejima T, et al. Interleukin 1 induces a shock-like state in rabbits. J Clin Invest 1988; 81:1162-1172.
45. Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice. J Exp Med 1988; 167: 1987-1992.
46. Faist E, Ertel W, Mewes A, et al. Trauma-induced alterations of the lymphokine cascade. In Faist E, Ninneman J, Green D, eds. Immune consequences of Trauma, Shock, and Sepsis. Berlin: Springer-Verlag, 1989, p 79.